Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TERN

Terns Pharmaceuticals Inc

Mar 27 • 04:00PM ET

52.92

-0.25 -0.47 %

Healthcare • Biotechnology • USA • NASD

Mar 27, 10:00 AMMerck to acquire Terns Pharmaceuticals for $53 per share as BMO Capital, Mizuho cut ratings to neutral-equivalent with $53 price targets

Peers: MDGL VKTX AKRO MNOV LGND GLMD BCRX XBIT ACAD AMRN

| Held by: VTI IWM IWN VXF IBB SCHA VTWO IWC IHE DFMC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.03	Insider Own	9.95%	Shs Outstand	106.33M	Perf Week	9.25%
Market Cap	5.63B	Forward P/E	-	EPS next Y	-1.16	Insider Trans	-1.82%	Shs Float	95.75M	Perf Month	29.33%
Enterprise Value	5.33B	PEG	-	EPS next Q	-0.28	Inst Own	108.85%	Short Float	19.00%	Perf Quarter	24.87%
Income	-94.44M	P/S	-	EPS this Y	4.87%	Inst Trans	40.30%	Short Ratio	4.77	Perf Half Y	611.29%
Sales	0.00M	P/B	16.30	EPS next Y	-8.45%	ROA	-27.78%	Short Interest	18.19M	Perf YTD	30.99%
Book/sh	3.25	P/C	19.03	EPS next 5Y	-8.13%	ROE	-29.12%	52W High	53.19 -0.51%	Perf Year	1596.15%
Cash/sh	2.78	P/FCF	-	EPS past 3/5Y	17.43% 16.38%	ROIC	-33.18%	52W Low	1.87 2737.53%	Perf 3Y	460.59%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	2.67% 5.20%	Perf 5Y	162.50%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	12.45%	Oper. Margin	-	ATR (14)	2.26	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	19.52	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	76.73	Recom	2.20
Dividend Gr. 3/5Y	- -	Current Ratio	19.52	EPS Q/Q	4.75%	SMA20	13.27%	Beta	-0.39	Target Price	54.62
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	28.24%	Rel Volume	2.08	Prev Close	53.17
Employees	59	LT Debt/Eq	0.00	Earnings	Nov 10 AMC	SMA200	143.96%	Avg Volume	3.81M	Price	52.92
IPO	Feb 05, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.26% -	Trades		Volume	7,922,225	Change	-0.47%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-25-26	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-09-26	Initiated	Leerink Partners	Outperform	$58
Nov-04-25	Upgrade	H.C. Wainwright	Neutral → Buy	$20
Nov-03-25	Upgrade	William Blair	Mkt Perform → Outperform
Oct-15-25	Initiated	Truist	Buy	$20
Sep-17-25	Initiated	Barclays	Overweight	$15
Sep-04-25	Resumed	H.C. Wainwright	Neutral
Feb-28-25	Initiated	William Blair	Mkt Perform
Oct-31-24	Initiated	Oppenheimer	Outperform	$82
Jun-22-23	Initiated	Mizuho	Buy	$16
Jun-07-23	Initiated	Jefferies	Buy	$18
May-31-23	Initiated	ROTH MKM	Buy	$23
May-08-23	Initiated	BMO Capital Markets	Outperform	$18
Feb-14-23	Initiated	JMP Securities	Mkt Outperform	$17
Feb-07-23	Initiated	UBS	Buy	$19
Sep-12-22	Initiated	H.C. Wainwright	Neutral	$6
Sep-14-21	Resumed	Goldman	Buy	$21
Mar-02-21	Initiated	JP Morgan	Overweight	$32
Mar-02-21	Initiated	Goldman	Buy	$29
Mar-02-21	Initiated	Cowen	Outperform

Show Previous Ratings

Mar-27-26 09:46AM	Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst calls (The Fly)
Mar-26-26 10:50AM	Are TERN, CRBG, EQH Obtaining Fair Deals for their Shareholders? (PR Newswire)
08:10AM	Mercks deal for Terns sparks debate over a possible biotech bidding war (BioPharma Dive)
12:01AM	Merck Preps for End of Keytruda Exclusivity with $6.7B Deal for Leukemia Treatment (The Daily Upside)
Mar-25-26 11:49AM	MSD spends $6.7bn to buy Terns Pharmaceuticals in cancer pipeline reinforcement (Pharmaceutical Technology) +5.72%
11:23AM	Loading…
11:23AM	Nasdaq bounces as oil price softens as US pushes for Iran talks (Proactive) +5.72%
10:41AM	Merck to acquire Terns Pharmaceuticals for $6.7B (Proactive) +5.72%
09:39AM	Merck buying Terns in $6.7B deal to bolster its cancer portfolio before key Keytruda patent expires (Associated Press Finance) +5.72%
07:35AM	Merck makes a big move into new cancer treatments with a $6.7 billion buyout deal (MarketWatch) +5.72%
07:21AM	Merck to buy oncology firm Terns Pharmaceuticals in $6.7 billion deal (Investing.com) +5.72%
06:49AM	Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns (The Wall Street Journal) +5.72%
06:45AM	Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) (Business Wire) +5.72%
04:50AM	Merck to buy Terns in $6.7B bet on a differentiated leukemia drug (BioPharma Dive) +5.72%
Feb-27-26 04:04PM	Analyst Optimistic on Terns (TERN) Citing Possible $4.8B Market for Upcoming Leukemia Drug (Insider Monkey)
Feb-25-26 04:05PM	Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences (GlobeNewswire)
09:06AM	Loading…
Feb-23-26 09:06AM	Viatris Stock to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-04-26 09:55AM	Wall Street Analysts See a 50.91% Upside in Terns Pharmaceuticals (TERN): Can the Stock Really Move This High? (Zacks) -6.39%
Feb-02-26 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.42%
04:16AM	Terns Pharmaceuticals (TERN) Eyes Expansion Beyond China Amid Strong Analyst Sentiment (Insider Monkey) +6.42%
Jan-23-26 05:27AM	Novo climbs higher on strong Wegovy pill launch; Terns tweaks leukemia drug deal (BioPharma Dive)
Jan-15-26 11:35AM	Wall Street Forecasts 42.31% Upside To Terns Pharmaceuticals, Inc. (TERN) (Insider Monkey)
Jan-11-26 01:00AM	Citizens Maintains An Outperform Rating On Terns Pharmaceuticals, Inc. (TERN) (Insider Monkey)
Jan-07-26 04:05PM	Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-26 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Dec-19-25 03:14PM	Jim Cramer Highlights Massive Gains for Terns Pharmaceuticals Shareholders (Insider Monkey)
Dec-15-25 06:47PM	Terns CEO Amy Burroughs talks cancer drug trial win (CNBC TV)
Dec-14-25 02:40PM	Terns Pharmaceuticals (TERN) Climbs 53% on Stellar Leukemia Treatment Trial (Insider Monkey)
Dec-11-25 04:05PM	Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-09-25 11:30PM	Terns Announces Pricing of Upsized $650 Million Public Offering (GlobeNewswire)
03:31PM	Cancer Study Buoys These Small Biotechs (Barrons.com)
02:23PM	Loading…
02:23PM	Terns (TERN) Hits All-Time High on Stellar Leukemia Treatment Results (Insider Monkey)
06:12AM	Terns Announces Proposed Public Offering (GlobeNewswire)
Dec-08-25 02:45PM	Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting (GlobeNewswire)
Dec-04-25 07:57AM	These stocks are new additions to Mizuhos Americas Top Picks list (Investing.com)
Nov-23-25 07:02AM	BMO Believes Market Undervalues Terns Pharmaceuticals (TERN) Despite Strong Trial Data (Insider Monkey)
Nov-18-25 12:43AM	Terns Pharmaceuticals (TERN) Soars to New Record High of $26.12 (Insider Monkey)
Nov-17-25 12:15PM	William Blair Reiterates a Buy on Terns Pharmaceuticals (TERN) (Insider Monkey)
Nov-14-25 04:05PM	Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-10-25 04:05PM	Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Nov-04-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-03-25 09:05AM	Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting (GlobeNewswire)
Oct-24-25 04:58AM	Chugai buys a kidney biotech; ICER targets rising launch prices (BioPharma Dive)
Oct-21-25 04:05PM	Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity (GlobeNewswire)
Oct-02-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Sep-21-25 10:45AM	2 Under-the-Radar Stocks That Could Soar (Motley Fool)
Aug-21-25 04:05PM	Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025 (GlobeNewswire)
Aug-07-25 09:55AM	Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors (Benzinga)
Aug-05-25 04:05PM	Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Aug-04-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jun-23-25 04:07PM	Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions (GlobeNewswire)
May-29-25 04:05PM	Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-14-25 09:30AM	Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701 (GlobeNewswire)
May-09-25 07:54AM	Is Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-08-25 04:05PM	Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-02-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Apr-30-25 04:05PM	Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference (GlobeNewswire)
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Apr-07-25 09:35AM	Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround (Zacks)
Apr-03-25 09:35AM	Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN) (Zacks)
Apr-02-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Mar-26-25 12:00PM	All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy (Zacks)
Mar-20-25 04:05PM	Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates (GlobeNewswire)
Mar-09-25 10:03AM	This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street (Motley Fool)
Feb-26-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Feb-25-25 08:05AM	Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference (GlobeNewswire)
03:00AM	Its CEO died. The company scrapped a promising program. Now, for their 2nd act. (Pharma Voice)
Feb-24-25 04:05PM	Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer (GlobeNewswire)
Feb-20-25 04:05PM	Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors (GlobeNewswire)
Feb-05-25 04:05PM	Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-03-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-08-25 04:05PM	Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Dec-16-24 01:10PM	Is Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
Dec-03-24 07:00AM	Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia (GlobeNewswire)
Dec-02-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-18-24 04:05PM	Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors (GlobeNewswire)
Nov-12-24 04:05PM	Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Nov-06-24 04:05PM	Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Sep-24-24 03:22AM	Insiders Snap Up These 2 Strong Buy Stocks (TipRanks)
Sep-18-24 10:07AM	This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments (Motley Fool)
Sep-17-24 01:30AM	OrbiMed Advisors LLC Increases Stake in Terns Pharmaceuticals Inc (GuruFocus.com)
Sep-15-24 07:21AM	Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now. (Motley Fool)
06:09AM	Should You Invest in This Under-the-Radar Weight Loss Stock? (Motley Fool)
Sep-14-24 10:12AM	1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More (Motley Fool)
Sep-12-24 07:00PM	Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Sep-10-24 10:50PM	Terns Announces Pricing of Upsized $150.15 Million Public Offering (GlobeNewswire)
04:52AM	Terns Pharmaceuticals reports positive data from Phase I trial of obesity treatment (Clinical Trials Arena)
Sep-09-24 04:01PM	Terns Announces Proposed Public Offering (GlobeNewswire)
09:58AM	Terns Pharmaceuticals Stock Is Soaring on Good Data for Weight-Loss Pill (Barrons.com)
09:24AM	Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month (Benzinga)
08:06AM	Early study data puts Terns among obesity drug contenders (BioPharma Dive)
07:05AM	Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity (GlobeNewswire)
Aug-28-24 09:55AM	Wall Street Analysts Think Terns Pharmaceuticals (TERN) Could Surge 78.74%: Read This Before Placing a Bet (Zacks)
Aug-05-24 09:56PM	TERN Stock Earnings: Terns Pharma Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Aug-02-24 01:54PM	3 Biotech Stocks That Could Have Investors Grinning Soon (InvestorPlace)
Aug-01-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jul-29-24 04:05PM	Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition (GlobeNewswire)
Jul-26-24 06:40PM	Burger King Parent Company and More Stocks See Action From Activist Investors (Barrons.com)

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burroughs Amy L.	Chief Executive Officer	Mar 16 '26	Option Exercise	4.64	14,583	67,665	303,559	Mar 17 06:10 PM
Burroughs Amy L.	Chief Executive Officer	Mar 16 '26	Sale	46.71	14,583	681,108	288,976	Mar 17 06:10 PM
Burroughs Amy L.	Chief Executive Officer	Feb 17 '26	Option Exercise	4.64	14,583	67,665	303,559	Feb 18 07:01 PM
Burroughs Amy L.	Chief Executive Officer	Feb 17 '26	Sale	39.19	14,583	571,579	288,976	Feb 18 07:01 PM
Burroughs Amy L.	Chief Executive Officer	Jan 15 '26	Option Exercise	4.64	68,749	318,995	357,725	Jan 16 05:22 PM
Burroughs Amy L.	Chief Executive Officer	Jan 15 '26	Sale	37.07	68,749	2,548,603	288,976	Jan 16 05:22 PM
AMY BURROUGHS	Director	Jan 15 '26	Proposed Sale	37.18	97,915	3,640,480		Jan 15 04:24 PM
Burroughs Amy L.	Chief Executive Officer	Jan 02 '26	Option Exercise	4.64	21,551	99,997	60,315	Jan 06 08:26 PM
Burroughs Amy L.	Chief Executive Officer	Jan 05 '26	Sale	38.10	71,339	2,718,230	138,976	Jan 06 08:26 PM
Kuriakose Emil	Chief Medical Officer	Jan 02 '26	Sale	38.57	1,155	44,552	50,365	Jan 06 08:25 PM
Quigley Jill M.	Director	Nov 04 '25	Option Exercise	9.24	24,520	226,565	24,520	Nov 05 06:17 PM
Quigley Jill M.	Director	Nov 04 '25	Sale	18.00	24,520	441,360	0	Nov 05 06:17 PM
JILL QUIGLEY	Director	Nov 04 '25	Proposed Sale	14.03	24,520	344,016		Nov 04 04:32 PM
Kuriakose Emil	Chief Medical Officer	Oct 01 '25	Sale	7.85	944	7,407	51,520	Oct 02 07:24 PM
Kuriakose Emil	Chief Medical Officer	Jul 01 '25	Sale	4.27	853	3,640	52,464	Jul 03 02:55 PM
Gengos Andrew	Chief Financial Officer	Jun 27 '25	Buy	3.93	10,000	39,283	25,000	Jun 30 05:38 PM
Burroughs Amy L.	Chief Executive Officer	Jun 25 '25	Buy	3.87	23,314	90,230	47,083	Jun 25 06:08 PM
Gengos Andrew	Chief Financial Officer	Jun 13 '25	Buy	3.73	10,000	37,350	10,000	Jun 16 06:05 PM
Gengos Andrew	Chief Financial Officer	Jun 16 '25	Buy	3.95	5,000	19,732	15,000	Jun 16 06:05 PM
Kuriakose Emil	Chief Medical Officer	Apr 01 '25	Sale	2.49	952	2,366	53,317	Apr 02 06:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TERN

Terns Pharmaceuticals Inc

Upgrade your FINVIZ experience